<PAGE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: SEPTEMBER 3, 1998
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. announced preliminary results of research
regarding melanoma treatment, as more fully described in the Company's Press
Release dated September 3, 1998, filed as Exhibit 99 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated September 3, 1998, announcing
preliminary results of research regarding melanoma treatment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
-----------------------------
Date: September 3, 1998 John Smolik, President
-1-
<PAGE>
EXHIBIT INDEX
Exhibit
No. Description
- --- -----------
99 Press release of the Company, dated September 3, 1998, announcing
preliminary results of research regarding melanoma treatment.
-2-
<PAGE>
EXHIBIT 99
Photogen Technologies, Inc.
7327 Oak Ridge Highway
Knoxville, TN 37931
Voice: 423-769-4012
Fax: 423-769-4013
Internet: www.photogen.com
RESEARCH SUGGESTS POSSIBLE NEW TREATMENT FOR MELANOMAS
Tumor Volumes Reduced by 100 Percent in Laboratory Mice Testing
KNOXVILLE, TENN.-- September 3, 1998-- At an industry conference today, Photogen
Technologies, Inc.(OTC:PHGN) presented the results of research in which melanoma
cells in laboratory mice were destroyed by activating naturally occurring
melanin and related compounds with the company's proprietary multi-photon
excitation technology.
Craig Dees, Ph.D., a senior research scientist at Photogen, presented a paper on
the results of this research to the World Association for Laser Therapy meeting
in Kansas today.
The tumors were treated by scanning the affected area with light from an
ultrafast pulsed laser. Tumors ranging in size from 6 to 10 mm in diameter and
up to 3 mm deep, when treated with ultrafast pulsed laser light, produced a
visible "blanching" effect, resulting from the interaction between melanin and
the light. After treatment, tumor volume was reduced by 100 percent with little
or no scarring. Tumors treated with conventional, continuous wave, laser light
produced only a minimal response. Results of a single treatment showed that
mice with tumors 6 to 10 mm in diameter and 3 mm deep showed no evidence of
tumor recurrence after three weeks. Tumors 5 to 7 mm deep have shown some
recurrence three weeks after treatment, and larger tumors reappeared even
sooner. The company will evaluate the effect of multiple treatments on the
larger and deeper tumors.
"These preliminary animal tests suggest that it may be possible to treat
melanomas without surgery or chemotherapy," said John Smolik, Photogen's
president. "If further pre-clinical results are consistent with these
preliminary results, we will seek opportunities to convert these developments
into an FDA-approved product that could benefit many people suffering from
melanoma."
<PAGE>
The company will continue to identify optimal light doses, activation
wavelength, treatment time and scan patterns for treatment of melanomas.
Photogen's scientists are working toward the development of its proprietary
multi-photon excitation technology to enhance the safety and efficacy of
photodynamic therapy for the diagnosis and treatment of cancer, infectious
diseases and other medical conditions.
Photogen Technologies, Inc., through its wholly owned subsidiary -- Photogen,
Inc. -- is a development-stage company focused on creating photodynamic-related
health care products based on its proprietary two-photon excitation and related
technology. The company has discovered new methods for using laser-generated
light to activate photoactive agents within deep tissue sufficient to produce a
range of beneficial therapeutic and diagnostic outcomes. These technologies
involve methods, materials and devices that may be used to produce light and
photoactive agents that will destroy diseased cells, remove tissue or identify
and diagnose disease.
This news release may contain forward-looking statements that involve risks and
uncertainties. The company has no products or operating revenues at this time.
A full discussion of the company's operations and financial condition, including
risk factors that may affect the company's business and future prospects, is
contained in documents the company files with the Securities and Exchange
Commission, such as the company's reports on Form 10-QSB, Form 10-KSB and Form
8-K. These documents identify important factors that could cause the company's
actual performance to differ from current expectations. The common stock of
Photogen Technologies, Inc. is traded on the over-the-counter bulletin board
market under the symbol PHGN.
For information, contact Robert Cathey at Ackermann Public Relations &
Marketing, 423/584-0550, e-mail:[email protected]. Or, visit our World
Wide Web site, at www.photogen.com.
Photogen is a trademark of Photogen Technologies, Inc.
Contact: Ackermann Public Relations & Marketing, Knoxville
Robert Cathey, 423/584-0550 or [email protected]
